And we shouldn't forget that inflammatory bowel disease and ARDS are included in Dr Krause's advisory remit on regulatory strategies. From the Mesoblast press release:
"Dr. Krause will advise the company on its regulatory strategies related to broadening out the remestemcel-L platform, including the ground-breaking treatment for steroid-refractory acute graft versus host disease (SR-aGVHD), inflammatory bowel disease and inflammatory lung disease, and the second-generation platform rexlemestrocel-L, including the Phase 3 product candidates for discogenic chronic lower back pain and inflammatory heart failure."
And we shouldn't forget that inflammatory bowel disease and ARDS...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.020(1.73%) |
Mkt cap ! $1.341B | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.21 | $1.17 | $16.67M | 14.04M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 54704 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.19 |
Change
0.020 ( 3.40 %) |
||||
| Open | High | Low | Volume | ||
| $1.21 | $1.21 | $1.17 | 2927691 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| MSB (ASX) Chart |